{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T22:40:09Z","timestamp":1747953609085,"version":"3.41.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2015,4,25]],"date-time":"2015-04-25T00:00:00Z","timestamp":1429920000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Pharm"],"published-print":{"date-parts":[[2015,10]]},"DOI":"10.1007\/s11096-015-0124-1","type":"journal-article","created":{"date-parts":[[2015,4,24]],"date-time":"2015-04-24T06:16:17Z","timestamp":1429856177000},"page":"808-814","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Efficiency of adalimumab, etanercept and infliximab in ankylosing spondylitis in clinical practice"],"prefix":"10.1007","volume":"37","author":[{"given":"Vicente","family":"Escudero-Vilaplana","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Esther","family":"Ram\u00edrez-Herr\u00e1iz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Estefan\u00eda","family":"Ala\u00f1\u00f3n-Plaza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicol\u00e1s","family":"Trovato-L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosario","family":"Garc\u00eda-Vicu\u00f1a","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis","family":"Carre\u00f1o-P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto","family":"Morell-Baladr\u00f3n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda","family":"Sanjurjo-S\u00e1ez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,4,25]]},"reference":[{"issue":"1","key":"124_CR1","first-page":"1","volume":"18","author":"MA Khan","year":"1992","unstructured":"Khan MA. An overview of clinical spectrum and heterogeneity of spondyloarthropathies. Rheum Dis Clin North Am. 1992;18(1):1\u201310.","journal-title":"Rheum Dis Clin North Am"},{"issue":"6","key":"124_CR2","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1177\/1759720X12458372","volume":"4","author":"IE Horst-Bruinsma van der","year":"2012","unstructured":"van der Horst-Bruinsma IE, Nurmohamed MT. Management and evaluation of extra-articular manifestations in spondyloarthritis. Ther Adv Musculoskelet Dis. 2012;4(6):413\u201322.","journal-title":"Ther Adv Musculoskelet Dis"},{"issue":"4","key":"124_CR3","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1097\/01.bor.0000231899.81677.04","volume":"18","author":"JD Reveille","year":"2006","unstructured":"Reveille JD. The genetic basis of ankylosing spondylitis. Curr Opin Rheumatol. 2006;18(4):332\u201341.","journal-title":"Curr Opin Rheumatol"},{"issue":"52","key":"124_CR4","first-page":"263","volume":"10","author":"GP Thomas","year":"2010","unstructured":"Thomas GP, Brown MA. Genomics of ankylosing spondylitis. Discov Med. 2010;10(52):263\u201371.","journal-title":"Discov Med"},{"issue":"12","key":"124_CR5","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1136\/ard.2002.004861","volume":"62","author":"AM Chorus","year":"2003","unstructured":"Chorus AM, Miedema HS, Boonen A, Van Der Linden S. Quality of life and work in patients with rheumatoid arthritis and ankylosing spondylitis of working age. Ann Rheum Dis. 2003;62(12):1178\u201384.","journal-title":"Ann Rheum Dis"},{"issue":"4 Suppl 55","key":"124_CR6","first-page":"S108","volume":"27","author":"U Kiltz","year":"2009","unstructured":"Kiltz U, van der Heijde D. Health-related quality of life in patients with rheumatoid arthritis and in patients with ankylosing spondylitis. Clin Exp Rheumatol. 2009;27(4 Suppl 55):S108\u201311.","journal-title":"Clin Exp Rheumatol"},{"key":"124_CR7","first-page":"4","volume":"78","author":"A Boonen","year":"2006","unstructured":"Boonen A, van der Linden SM. The burden of ankylosing spondylitis. J Rheumatol Suppl. 2006;78:4\u201311.","journal-title":"J Rheumatol Suppl"},{"issue":"5","key":"124_CR8","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1002\/1529-0131(200110)45:5<424::AID-ART361>3.0.CO;2-7","volume":"45","author":"JH Barlow","year":"2001","unstructured":"Barlow JH, Wright CC, Williams B, Keat A. Work disability among people with ankylosing spondylitis. Arthritis Rheum. 2001;45(5):424\u20139.","journal-title":"Arthritis Rheum"},{"issue":"5","key":"124_CR9","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1136\/ard.61.5.429","volume":"61","author":"A Boonen","year":"2002","unstructured":"Boonen A, van der Heijde D, Landewe R, Spoorenberg A, Schouten H, Rutten-van M\u00f6lken M, et al. Work status and productivity costs due to ankylosing spondylitis: comparison of three European countries. Ann Rheum Dis. 2002;61(5):429\u201337.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"124_CR10","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1136\/ard.2011.151027","volume":"70","author":"J Braun","year":"2011","unstructured":"Braun J, van den Berg R, Baraliakos X, Boehm H, Burgos-Vargas R, Collantes-Estevez E, et al. 2010 update of the ASAS\/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis. 2011;70(6):896\u2013904.","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 3","key":"124_CR11","doi-asserted-by":"crossref","first-page":"iii8","DOI":"10.1136\/ard.61.suppl_3.iii8","volume":"61","author":"J Sieper","year":"2002","unstructured":"Sieper J, Braun J, Rudwaleit M, Boonen A, Zink A. Ankylosing spondylitis: an overview. Ann Rheum Dis. 2002;61(Suppl 3):iii8\u201318.","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"124_CR12","first-page":"2286","volume":"21","author":"S Garrett","year":"1994","unstructured":"Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol. 1994;21(12):2286\u201391.","journal-title":"J Rheumatol"},{"issue":"3","key":"124_CR13","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1136\/ard.2005.040758","volume":"65","author":"J Braun","year":"2006","unstructured":"Braun J, Davis J, Dougados M, Sieper J, van der Linden S, van der Heijde D. First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis. Ann Rheum Dis. 2006;65(3):316\u201320.","journal-title":"Ann Rheum Dis"},{"key":"124_CR14","author":"K Chatzidionysiou","year":"2014","unstructured":"Chatzidionysiou K, Askling J, Eriksson J, Kristensen LE, van Vollenhoven R. Effectiveness of TNF inhibitor switch in RA: results from the national Swedish register. Ann Rheum Dis. 2014. doi: 10.1136\/annrheumdis-2013-204714 .","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"124_CR15","first-page":"96","volume":"29","author":"A R\u00e9my","year":"2011","unstructured":"R\u00e9my A, Avouac J, Gossec L, Combe B. Clinical relevance of switching to a second tumour necrosis factor-alpha inhibitor after discontinuation of a first tumour necrosis factor-alpha inhibitor in rheumatoid arthritis: a systematic literature review and meta-analysis. Clin Exp Rheumatol. 2011;29(1):96\u2013103.","journal-title":"Clin Exp Rheumatol"},{"issue":"12","key":"124_CR16","first-page":"2525","volume":"29","author":"MA Fitzcharles","year":"2002","unstructured":"Fitzcharles MA, Clayton D, Menard HA. The use of infliximab in academic rheumatology practice: an audit of early clinical experience. J Rheumatol. 2002;29(12):2525\u201330.","journal-title":"J Rheumatol"},{"issue":"10","key":"124_CR17","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1007\/s10067-010-1542-z","volume":"29","author":"J Lee","year":"2010","unstructured":"Lee J, Noh JW, Hwang JW, Oh JM, Kim H, Ahn JK, et al. Extended dosing of etanercept 25\u00a0mg can be effective in patients with ankylosing spondylitis: a retrospective analysis. Clin Rheumatol. 2010;29(10):1149\u201354.","journal-title":"Clin Rheumatol"},{"issue":"8","key":"124_CR18","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1007\/s00296-011-1920-0","volume":"32","author":"J Moghimi","year":"2012","unstructured":"Moghimi J, Sheikhvatan M, Semnani V. The use of low-dose etanercept as an alternative therapy for treatment of ankylosing spondylitis: a case series. Rheumatol Int. 2012;32(8):2271\u20134.","journal-title":"Rheumatol Int"},{"issue":"1","key":"124_CR19","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.jbspin.2010.04.017","volume":"78","author":"G Tenga","year":"2011","unstructured":"Tenga G, Goeb V, Lequerre T, Bacquet-Deschryver H, Daragon A, Pouplin S, et al. A 3\u00a0mg\/kg starting dose of infliximab in active spondyloarthritis resistant to conventional treatments is efficient, safe and lowers costs. Joint Bone Spine. 2011;78(1):50\u20135.","journal-title":"Joint Bone Spine"},{"issue":"4","key":"124_CR20","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/art.1780270401","volume":"27","author":"S Linden van der","year":"1984","unstructured":"van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum. 1984;27(4):361\u20138.","journal-title":"Arthritis Rheum"},{"issue":"6","key":"124_CR21","first-page":"372","volume":"31","author":"R Ariza-Ariza","year":"2004","unstructured":"Ariza-Ariza R, Hernandez-Cruz B, Navarro-Sarabia F. The Spanish version of the BASDAI is reliable and correlates with disease activity in patients with ankylosing spondylitis. Rev Esp Reumatol. 2004;31(6):372\u20138.","journal-title":"Rev Esp Reumatol"},{"issue":"3","key":"124_CR22","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1136\/ard.2007.075879","volume":"67","author":"J Braun","year":"2008","unstructured":"Braun J, Baraliakos X, Listing J, Fritz C, Alten R, Burmester G, et al. Persistent clinical efficacy and safety of anti-tumour necrosis factor alpha therapy with infliximab in patients with ankylosing spondylitis over 5\u00a0years: evidence for different types of response. Ann Rheum Dis. 2008;67(3):340\u20135.","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"124_CR23","doi-asserted-by":"crossref","first-page":"3230","DOI":"10.1002\/art.11325","volume":"48","author":"JC Davis Jr","year":"2003","unstructured":"Davis JC Jr, Van Der Heijde D, Braun J, Dougados M, Cush J, Clegg DO, et al. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis Rheum. 2003;48(11):3230\u20136.","journal-title":"Arthritis Rheum"},{"issue":"3","key":"124_CR24","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1136\/ard.2007.078139","volume":"67","author":"JC Davis Jr","year":"2008","unstructured":"Davis JC Jr, van der Heijde DM, Braun J, Dougados M, Clegg DO, Kivitz AJ, et al. Efficacy and safety of up to 192\u00a0weeks of etanercept therapy in patients with ankylosing spondylitis. Ann Rheum Dis. 2008;67(3):346\u201352.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"124_CR25","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1002\/art.20852","volume":"52","author":"D Heijde van der","year":"2005","unstructured":"van der Heijde D, Dijkmans B, Geusens P, Sieper J, DeWoody K, Williamson P, et al. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum. 2005;52(2):582\u201391.","journal-title":"Arthritis Rheum"},{"issue":"7","key":"124_CR26","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1002\/art.21913","volume":"54","author":"D Heijde van der","year":"2006","unstructured":"van der Heijde D, Kivitz A, Schiff MH, Sieper J, Dijkmans BA, Braun J, et al. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2006;54(7):2136\u201346.","journal-title":"Arthritis Rheum"},{"key":"124_CR27","unstructured":"The Association of British Pharmaceutical Industry. The vision for real world data\u2014harnessing the opportunities in the UK. Demonstrating value with real world data. White paper: September 2011. http:\/\/www.abpi.org.uk\/our-work\/library\/industry\/Documents\/Vision-for-Real-World-Data.pdf ."},{"issue":"2","key":"124_CR28","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s10067-007-0674-2","volume":"27","author":"SH Lee","year":"2008","unstructured":"Lee SH, Lee YA, Hong SJ, Yang HI. Etanercept 25\u00a0mg\/week is effective enough to maintain remission for ankylosing spondylitis among Korean patients. Clin Rheumatol. 2008;27(2):179\u201381.","journal-title":"Clin Rheumatol"},{"issue":"7","key":"124_CR29","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1007\/s10067-011-1722-5","volume":"30","author":"V Navarro-Compan","year":"2011","unstructured":"Navarro-Compan V, Moreira V, Ariza-Ariza R, Hernandez-Cruz B, Vargas-Lebron C, Navarro-Sarabia F. Low doses of etanercept can be effective in ankylosing spondylitis patients who achieve remission of the disease. Clin Rheumatol. 2011;30(7):993\u20136.","journal-title":"Clin Rheumatol"},{"issue":"7","key":"124_CR30","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.3899\/jrheum.111337","volume":"39","author":"J Paccou","year":"2012","unstructured":"Paccou J, Bacle-Boutry MA, Solau-Gervais E, Bele-Philippe P, Flipo RM. Dosage adjustment of anti-tumor necrosis factor-alpha inhibitor in ankylosing spondylitis is effective in maintaining remission in clinical practice. J Rheumatol. 2012;39(7):1418\u201323.","journal-title":"J Rheumatol"},{"issue":"8","key":"124_CR31","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1093\/rheumatology\/kem031","volume":"46","author":"MF Botteman","year":"2007","unstructured":"Botteman MF, Hay JW, Luo MP, Curry AS, Wong RL, van Hout BA. Cost effectiveness of adalimumab for the treatment of ankylosing spondylitis in the United Kingdom. Rheumatology (Oxford). 2007;46(8):1320\u20138.","journal-title":"Rheumatology (Oxford)"},{"issue":"8","key":"124_CR32","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1093\/rheumatology\/kem133","volume":"46","author":"RM Ara","year":"2007","unstructured":"Ara RM, Reynolds AV, Conway P. The cost-effectiveness of etanercept in patients with severe ankylosing spondylitis in the UK. Rheumatology (Oxford). 2007;46(8):1338\u201344.","journal-title":"Rheumatology (Oxford)"},{"issue":"11","key":"124_CR33","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1093\/rheumatology\/keq222","volume":"49","author":"AR Neilson","year":"2010","unstructured":"Neilson AR, Sieper J, Deeg M. Cost-effectiveness of etanercept in patients with severe ankylosing spondylitis in Germany. Rheumatology (Oxford). 2010;49(11):2122\u201334.","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"124_CR34","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1111\/j.1524-4733.2007.00252.x","volume":"11","author":"G Kobelt","year":"2008","unstructured":"Kobelt G, Sobocki P, Mulero J, Gratacos J, Pocovi A, Collantes-Estevez E. The burden of ankylosing spondylitis in Spain. Value Health. 2008;11(3):408\u201315.","journal-title":"Value Health"}],"container-title":["International Journal of Clinical Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-015-0124-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11096-015-0124-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-015-0124-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T22:11:17Z","timestamp":1747951877000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11096-015-0124-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4,25]]},"references-count":34,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2015,10]]}},"alternative-id":["124"],"URL":"https:\/\/doi.org\/10.1007\/s11096-015-0124-1","relation":{},"ISSN":["2210-7703","2210-7711"],"issn-type":[{"type":"print","value":"2210-7703"},{"type":"electronic","value":"2210-7711"}],"subject":[],"published":{"date-parts":[[2015,4,25]]}}}